

CurePSP, Inc.

Audited Financial Statements

June 30, 2025

CurePSP, Inc.

Audited Financial Statements

June 30, 2025

CONTENTS

	Page
Independent Auditor's Report	1-2
Financial Statements	
Statement of Financial Position	3
Statement of Activities	4
Statement of Functional Expenses	5
Statement of Cash Flows	6
Notes to Financial Statements	7-16

Independent Auditor's Report

To the Board of Directors
CurePSP, Inc.

Opinion

We have audited the financial statements of CurePSP, Inc. (the "Organization"), which comprise the statement of financial position as of June 30, 2025, the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Organization as of June 30, 2025, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Organization and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern within one year after the date that the financial statements are issued or available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Organization's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with Those Charged with Governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Report on Summarized Comparative Information

We have previously audited the Organization's 2024 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated April 2, 2025. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2024, is consistent, in all material respects, with the audited financial statements from which it has been derived.

Sax LLP

New York, NY
April 17, 2026

CurePSP, Inc.

Statement of Financial Position

As of June 30, 2025

(With comparative totals as of June 30, 2024)

	<u>June 30,</u>	
	<u>2025</u>	<u>2024</u>
ASSETS		
Cash and cash equivalents	\$ 2,589,958	\$ 555,913
Investments	7,437,379	6,754,760
Pledges receivable	19,105	314,706
Prepaid expenses and other assets	424,608	490,678
Security deposit	4,764	5,264
Property and equipment, net	151,438	204,692
Operating lease-right-of-use asset	32,838	-
Investments held for endowment	369,314	361,156
	<u>369,314</u>	<u>361,156</u>
TOTAL ASSETS	<u>\$ 11,029,404</u>	<u>\$ 8,687,169</u>
LIABILITIES AND NET ASSETS		
LIABILITIES		
Accounts payable and accrued expenses	\$ 555,796	\$ 197,082
Deferred revenue	223,513	248,513
Grants payable	327,262	688,177
Operating lease liabilities	32,838	-
Total liabilities	<u>1,139,409</u>	<u>1,133,772</u>
NET ASSETS		
Without donor restrictions	7,258,098	5,724,836
With donor restrictions - programs	2,262,583	1,464,600
With donor restrictions - endowment	369,314	363,961
Total net assets	<u>9,889,995</u>	<u>7,553,397</u>
TOTAL LIABILITIES AND NET ASSETS	<u>\$ 11,029,404</u>	<u>\$ 8,687,169</u>

The attached notes and auditor's report are an integral part of these financial statements.

CurePSP, Inc.

Statement of Activities

For the Year Ended June 30, 2025
(With comparative totals for the year ended June 30, 2024)

	Without Donor Restrictions	With Donor Restrictions	Total 6/30/25	Total 6/30/24
PUBLIC SUPPORT AND REVENUE				
Contributions	\$ 5,880,214	\$ 1,011,308	\$ 6,891,522	\$ 4,672,617
Fundraising event income	314,487	300,905	615,392	506,768
Investment return	634,794	35,025	669,819	816,732
Other revenue	25,718	-	25,718	30,447
Net assets released from restrictions	543,902	(543,902)	-	-
Total public support and revenue	<u>7,399,115</u>	<u>803,336</u>	<u>8,202,451</u>	<u>6,026,564</u>
EXPENSES				
Program services	4,752,756	-	4,752,756	3,900,876
General and administrative	594,283	-	594,283	514,482
Fundraising	518,814	-	518,814	430,560
Total expenses	<u>5,865,853</u>	<u>-</u>	<u>5,865,853</u>	<u>4,845,918</u>
Change in net assets	1,533,262	803,336	2,336,598	1,180,646
NET ASSETS, beginning of year	<u>5,724,836</u>	<u>1,828,561</u>	<u>7,553,397</u>	<u>6,372,751</u>
NET ASSETS, end of year	<u><u>\$ 7,258,098</u></u>	<u><u>\$ 2,631,897</u></u>	<u><u>\$ 9,889,995</u></u>	<u><u>\$ 7,553,397</u></u>

The attached notes and auditor's report are an integral part of these financial statements.

CurePSP, Inc.

Statement of Functional Expenses

For the Year Ended June 30, 2025

(With comparative totals for the year ended June 30, 2024)

	Program Services				Supporting Services			Total Expenses 06/30/25	Total Expenses 06/30/24
	Care	Consciousness	Cure	Total Program Services	General and Administrative	Fundraising	Total Supporting Services		
Salaries	\$ 496,109	\$ 424,956	\$ 387,693	\$ 1,308,758	\$ 156,672	\$ 207,058	\$ 363,730	\$ 1,672,488	\$ 1,361,373
Payroll taxes and benefits	118,970	101,908	92,971	313,849	23,212	49,654	72,866	386,715	327,397
Consultants and professional fees	16,175	90,179	22,277	128,631	235,622	9,000	244,622	373,253	310,153
Occupancy	17,430	19,408	14,062	50,900	3,995	10,314	14,309	65,209	59,846
Research grants	6,000	30,000	1,116,474	1,152,474	-	-	-	1,152,474	610,498
Brain tissue grants	-	-	36,192	36,192	-	-	-	36,192	217,310
Respite fund grants	221,269	-	-	221,269	-	-	-	221,269	88,432
Patient care	312,084	-	18,067	330,151	-	-	-	330,151	255,221
Research symposium production costs	-	-	291,903	291,903	-	-	-	291,903	314,950
Direct mail	75,360	75,360	75,360	226,080	-	75,358	75,358	301,438	399,780
Recruiting and marketing	15,037	67,710	9,529	92,276	2,011	23,104	25,115	117,391	142,034
Meeting and conferences	8,012	59,719	30,909	98,640	6,796	19,389	26,185	124,825	84,634
Materials and supplies	1,133	3,442	1,118	5,693	332	499	831	6,524	8,046
Equipment rental	-	-	-	-	1,951	-	1,951	1,951	2,003
Travel	29,840	67,064	83,011	179,915	27,131	35,131	62,262	242,177	197,099
Postage and shipping	2,826	43,125	2,041	47,992	759	13,558	14,317	62,309	55,744
Insurance	-	-	-	-	8,789	-	-	8,789	18,772
Technology expenses	36,423	71,646	34,111	142,180	11,482	56,544	68,026	210,206	198,160
Photography and videography	-	7,000	-	7,000	-	-	-	7,000	525
Depreciation	32,710	28,018	25,561	86,289	10,313	13,652	23,965	110,254	54,756
Other expenses	9,410	11,736	11,418	32,564	105,218	5,553	110,771	143,335	139,185
Total expenses for statement of activities	\$ 1,398,788	\$ 1,101,271	\$ 2,252,697	\$ 4,752,756	\$ 594,283	\$ 518,814	\$ 1,113,097	\$ 5,865,853	\$ 4,845,918

The attached notes and auditor's report are an integral part of these financial statements.

CurePSP, Inc.

Statement of Cash Flows

For the Year Ended June 30, 2025
(With comparative totals for the year ended June 30, 2024)

	June 30,	
	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$ 2,336,598	\$ 1,180,646
Adjustments to reconcile change in net assets to net cash provided by (used for) operating activities:		
Depreciation and amortization	110,254	54,756
Net realized and unrealized gain on investments	(300,706)	(643,198)
Changes in assets and liabilities:		
Pledges receivable	295,601	(244,935)
Prepaid expenses and other assets	66,070	(221,184)
Security deposit	500	6,500
Accounts payable and accrued expenses	358,714	(10,007)
Deferred revenue	(25,000)	25,000
Grants payable	(360,915)	(285,719)
Total adjustments	144,518	(1,318,787)
Net cash provided by (used for) operating activities	2,481,116	(138,141)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of investments (including reinvestment of interest and dividends)	(500,071)	(1,497,203)
Proceeds from sales of investments	110,000	1,410,867
Purchase of property and equipment	(57,000)	(173,800)
Net cash (used for) investing activities	(447,071)	(260,136)
Net increase/(decrease) in cash and cash equivalents	2,034,045	(398,277)
CASH AND CASH EQUIVALENTS, <i>beginning of year</i>	555,913	954,190
CASH AND CASH EQUIVALENTS, <i>end of year</i>	\$ 2,589,958	\$ 555,913
SUPPLEMENTAL CASH FLOW INFORMATION		
No interest or taxes were paid		

The attached notes and auditor's report are an integral part of these financial statements.

CurePSP, Inc.

Notes to Financial Statements

June 30, 2025

Note 1 - Organization

CurePSP, Inc. ("CurePSP"), formerly The Foundation for PSP | CBD and Related Brain Diseases, is a not-for-profit organization formed to promote and fund research with the purpose of finding the cause and cure as well as treatment and prevention for progressive supranuclear palsy ("PSP") and corticobasal degeneration ("CBD") and other related diseases. CurePSP provides information, education, support, and advocacy to persons with these disorders, their families, caregivers, and the general public. CurePSP awards research grants to scientists and educates physicians and other health professionals on PSP and CBD, and other related diseases and how to improve patient care. A majority of the revenue and support CurePSP receives is from individual, corporate, and foundation donors as well as from special events held throughout the year.

CurePSP has been notified by the Internal Revenue Service that it is a not-for-profit organization exempt from Federal income tax under Section 501(c)(3) of the Internal Revenue Code and has not been determined to be a private foundation as defined under Section 509(a)(1) of the Internal Revenue Code.

The primary sources of revenue are contributions, investment income and other miscellaneous income.

Note 2 - Summary of Significant Accounting Policies

a. Basis of Accounting

The financial statements of the Organization have been prepared using the accrual basis of accounting which is the process of recognizing revenue and expenses when earned or incurred rather than when received or paid.

b. Basis of Presentation

The financial statements are presented in accordance with the provisions of the FASB Accounting Standards Codification ("ASC") 958 - *Presentation of Financial Statements of Not-For-Profit Entities*. FASB ASC 958 requires the Organization to report information regarding its financial position and activities according to the following specific classes of net assets:

- *Net Assets without Donor Restrictions* - represents all activity without donor-imposed restrictions. The Board of Directors have established several board designated funds. See Note 7.
- *Net Assets with Donor Restrictions* - represents those resources, the uses of which have been restricted by donors to specific purposes or the passage of time and/or must remain intact, in perpetuity. The release from restrictions results from the satisfaction of the restricted purposes specified by the donor.

CurePSP, Inc.

Notes to Financial Statements

June 30, 2025

Note 2 - Summary of Significant Accounting Policies - Continued

c. Revenue Recognition

The Organization follows the requirements of the FASB ASC 958-605 for recording contributions, which are recognized at the time a contribution becomes unconditional in nature. Contributions are recorded in the net asset classes referred to above depending on the existence and/or nature of any donor-imposed restriction. When a restriction expires, that is, when a stipulated time restriction ends, or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions. If donor restricted contributions are satisfied in the same period they were received, they are classified as without donor restrictions.

Contributions may be subject to conditions which are defined as both a barrier to entitlement and a right of return of payments, or release from obligations, and are recognized as income once the conditions have been substantially met.

The Organization records promises to give as revenue in the period they become unconditional. Unconditional promises to give that are expected to be collected within one year are recorded at net realizable value. Long-term pledges are recorded at fair value using a risk-free discount rate, when deemed material. Conditional promises to give are recognized when the conditions on which they depend are substantially met. At June 30, 2025, all pledges receivables were due within one year.

Bequests are recorded as income at the time there is a legal right to such bequest and the amount is measurable.

Special event revenue is comprised of payments received from third parties to support and/or attend fundraising events. Special event revenue includes an exchange transaction component for the value of the goods or services rendered, which follows revenue recognition guidance under FASB ASC 606. The amount paid by third parties that is above the value of the goods or services is considered a contribution. Revenue is recognized at the time the fundraising event occurs. Historically there have been no significant bad debt losses from pledges receivable. Management evaluates the need for doubtful accounts based on past experience and considers the age of the receivable. Based on this evaluation, it has been determined that no allowance for doubtful accounts is necessary. Pledges receivables will be written-off directly to expense when all reasonable collection efforts have been exhausted.

d. Cash and Cash Equivalents

The Organization considers all liquid investments with an initial maturity of three months or less to be cash and cash equivalents except cash held as part of the Organization's investment portfolio.

e. Concentration of Credit Risk

Financial instruments which potentially subject the Organization to a concentration of credit risk consist of cash accounts and investments. These have all been placed with financial institutions that management deems to be creditworthy. At times, the balances at year end may exceed federally insured limits. Investments are subject to market fluctuations and principal is not guaranteed. The Organization has not sustained any losses due to the failure of any financial institution.

CurePSP, Inc.

Notes to Financial Statements

June 30, 2025

Note 2 - Summary of Significant Accounting Policies - Continued

f. Investment and Investment Return

Investments are recorded at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. Realized and unrealized gains and losses are reflected in the statement of activities.

g. Leases

The Organization determines if an arrangement is or contains a lease at inception. Leases are included in ROU assets and lease liabilities in the statement of financial position. ROU assets and lease liabilities reflect the present value of the future minimum lease payments over the lease term, and ROU assets also include prepaid or accrued rent. Operating lease expense is recognized on a straight-line basis over the lease term. The Organization does not report ROU assets and lease liabilities for its short-term leases (leases with a term of 12 months or less). Instead, the lease payments of those leases are reported as lease expense on a straight-line basis over the lease term. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Organization will exercise that option. The change in operating lease right-of-use asset and liability on the statement of cash flows includes the amortization of the ROU asset and accretion of the discounted lease liability.

h. Property and Equipment

Capital items purchased that have a useful life of more than one year and exceed \$2,500; whereby, the Organization has title to, are capitalized at cost. Depreciation is computed using the straight-line method over the estimated useful life of the respective assets as follows:

Website development	3 years
Software	5 years
Computers	5-7 years
Furniture and fixtures	5-7 years

i. Management Estimates

The preparation of the financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates.

CurePSP, Inc.

Notes to Financial Statements

June 30, 2025

Note 2 - Summary of Significant Accounting Policies - Continued

j. Functional Allocation of Expenses

The costs of providing various programs and other activities have been summarized on a functional basis in the accompanying financial statements. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

The following costs are allocated using time and effort as the basis:

- Salaries
- Payroll taxes and benefits
- Occupancy
- Meeting and conferences
- Materials and supplies
- Equipment rental
- Travel
- Postage and shipping
- Technology expenses
- Depreciation
- Other expenses

All other expenses have been charged directly to the applicable program or supporting services.

k. Advertising Costs

Advertising costs are expensed as incurred.

l. Donated Services

Contributions of services that create or enhance non-financial assets, or require specialized skills, are performed by those who possess those skills, and would typically have been purchased if they had not been donated are also recognized at fair value.

Many individuals volunteer their time and perform a variety of services to assist with specific assistance programs, campaign solicitation, and various committee assignments. No amounts have been reflected in the financial statements for these types of donated services because they do not meet the criteria for recognition as outlined above.

m. Accounting for Uncertainty of Income Taxes

The Organization does not believe its financial statements include any material, uncertain tax positions. Tax filings for periods ending June 30, 2022 and later are subject to examination by applicable taxing authorities.

CurePSP, Inc.

Notes to Financial Statements

June 30, 2025

Note 2 - Summary of Significant Accounting Policies - Continued

n. Prior Year summarized Comparative Information

The financial statements include certain prior year summarized comparative information in total but not by net asset class. Such information does not include sufficient detail to constitute a presentation in conformity with accounting principles generally accepted in the United States of America. Accordingly, such information should be read in conjunction with the Organization's financial statements for the year ended June 30, 2024, from which the summarized information was derived.

Note 3 - Investments and Fair Value Measurements

Accounting standards have established a fair value hierarchy giving the highest priority to quoted market prices in active markets and the lowest priority to unobservable data. The fair value hierarchy is categorized into three levels based on the inputs as follows:

Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Organization has the ability to access.

Level 2 - Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3 - Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The following summarizes the composition of investments:

	June 30, 2025			
	Level 1	Level 2	Level 3	Total
Cash	\$ 175,435	\$ -	\$ -	\$ 175,435
Equity funds	5,168,192	-	-	5,168,192
Mutual funds	374,110	-	-	374,110
Fixed income funds	2,023,021	-	-	2,023,021
Exchange-traded funds	65,935	-	-	65,935
Total	<u>\$ 7,806,693</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 7,806,693</u>
	June 30, 2024			
	Level 1	Level 2	Level 3	Total
Cash	\$ 634,897	\$ -	\$ -	\$ 634,897
Mutual funds	4,988,738	-	-	4,988,738
Exchange-traded funds	1,492,281	-	-	1,492,281
Total	<u>\$ 7,115,916</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 7,115,916</u>

CurePSP, Inc.

Notes to Financial Statements

June 30, 2025

Note 3 - Investments and Fair Value Measurements - Continued

The fair value of mutual funds, exchange-traded funds, fixed income funds were determined using Level 1 inputs, which were based on quoted prices in active markets. Management believes the fair value of these investments to be a reasonable approximation of their exit price. There were no Level 2 investments at June 30, 2025 or 2024.

Investment return consisted of the following:

	June 30,	
	2025	2024
Interest and dividends	\$ 369,113	\$ 173,534
Realized gain/(loss) on investments	1,529	(255,680)
Unrealized gain on investments	299,177	898,878
Total	<u>\$ 669,819</u>	<u>\$ 816,732</u>

Note 4 - Operating Lease Right-of-Use Asset and Operating Lease Liability

The Organization evaluated current contracts to determine which met the criteria of a lease. The Organization leases building space in New York City, under a non-cancelable lease, which expires May 31, 2026. This has been determined to be an operating lease. The lease includes an option to renew.

The ROU assets represent the Organization's right to use the underlying asset for the lease term, and the lease liabilities represent the Organization's obligation to make lease payments arising from this lease. The ROU assets and lease liabilities were calculated based on the present value of future lease payments over the lease terms. As of June 30, 2025, the weighted-average remaining lease term for the Organization's operating lease was 0.92 years. The Organization has made an accounting policy election to use a risk-free rate in lieu of its incremental borrowing rate to discount future lease payments. The weighted-average discount rate applied to calculate lease liabilities as of June 30, 2025 was 5.18%.

For the year ended June 30, 2025, total operating lease cost was \$31,586.

Cash paid for operating lease for the year ended June 30, 2025 was \$36,600. There were no noncash investing and financing transactions related to leasing.

The future payments due under the operating lease as of June 30, 2025 are as follows:

Total lease payments due for the year ending:	
June 30, 2026	\$ 33,550
Less: present value discount	(712)
Total	<u>\$ 32,838</u>

CurePSP, Inc.

Notes to Financial Statements

June 30, 2025

Note 5 - Property and Equipment

Property and equipment consists of the following:

	June 30,	
	2025	2024
Website development	\$ 489,296	\$ 432,296
Software	5,906	5,906
Computers	34,293	34,293
Furniture and fixtures	544	544
Total	530,039	473,039
Less accumulated depreciation	378,601	268,347
Net property and equipment	<u>\$ 151,438</u>	<u>\$ 204,692</u>

Note 6 - Net Assets with Donor Restrictions

The following summarizes the nature of net assets with donor restrictions:

	June 30,	
	2025	2024
Programs:		
Cure	\$ 1,928,785	\$ 1,319,295
Care	327,470	138,977
Consciousness	6,328	6,328
Total program	<u>2,262,583</u>	<u>1,464,600</u>
Restricted for endowment:		
Endowment funds - corpus	258,368	258,368
Endowment funds - accumulated earnings	110,946	105,593
Total restricted for endowment	<u>369,314</u>	<u>363,961</u>
Total	<u>\$ 2,631,897</u>	<u>\$ 1,828,561</u>

Note 7 - Net assets with Donor Restrictions - Endowment Funds

CurePSP's endowment includes a specific donor restricted fund to be held in perpetuity to fund students involved in researching a cause and a remedy for progressive supranuclear palsy, and thereafter in medically appropriate research.

Interpretation of Relevant Law

CurePSP follows the Uniform Prudent Management of Institutional Funds Act ("UPMIFA"). The Board of Directors of CurePSP has interpreted UPMIFA as requiring certain amounts to be retained indefinitely. Absent explicit donor stipulations to the contrary, CurePSP will preserve the fair value of the original gift as of the gift date for all donor-restricted endowment funds. However, under certain circumstances, CurePSP has the right to appropriate for expenditure the fair value of the original gift in a manner consistent with the standard of prudence specifically prescribed by UPMIFA.

CurePSP, Inc.

Notes to Financial Statements

June 30, 2025

Note 7 - Net assets with Donor Restrictions - Endowment Funds - Continued

As a result of this interpretation, CurePSP classifies as net assets with donor restrictions: (a) the original value of gifts donated to the endowment, (b) the original value of subsequent gifts to the endowment, and (c) accumulations to the endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund, less (d) appropriations in accordance with donor directives.

When endowment funds have earnings in excess of amounts that need to be retained as part of the corpus, their earnings are restricted until the board appropriates for expenditures; therefore, they have been classified in the class of net assets with donor restrictions.

Spending Policies

In accordance with UPMIFA, CurePSP considers the following factors in determining amounts to be appropriated for expenditure:

- (1) The duration and preservation of the fund;
- (2) The purposes of CurePSP and the donor-restricted endowment fund;
- (3) General economic conditions;
- (4) The possible effect of inflation and deflation;
- (5) The expected total return from income and the appreciation of investments;
- (6) Other resources of CurePSP;
- (7) The investment policies of CurePSP;
- (8) Where appropriate and circumstances would otherwise warrant, alternatives to expenditure of the endowment fund, giving due consideration to the effect that such alternatives may have on CurePSP.

CurePSP, Inc.

Notes to Financial Statements

June 30, 2025

Note 7 - Net Assets with Donor Restrictions - Endowment Funds - Continued

Changes in endowment net assets were as follows:

	June 30, 2025		
	Endowment Earnings	Endowment Corpus	Total
Endowment, beginning of year	\$ 105,593	\$ 258,368	\$ 363,961
Board appropriations	(29,672)	-	(29,672)
Net investment income	35,025	-	35,025
Endowment, end of year	<u>\$ 110,946</u>	<u>\$ 258,368</u>	<u>\$ 369,314</u>

	June 30, 2024		
	Endowment Earnings	Endowment Corpus	Total
Endowment, beginning of year	\$ 99,231	\$ 258,368	\$ 357,599
Board appropriations	(35,310)	-	(35,310)
Net investment income	41,672	-	41,672
Endowment, end of year	<u>\$ 105,593</u>	<u>\$ 258,368</u>	<u>\$ 363,961</u>

Endowment Investment Policies

CurePSP has adopted an investment policy for endowment assets that relies on the accumulation of interest, dividends, and other market value gains for future appropriation. CurePSP's policy is to not spend from underwater endowments unless directed otherwise by the donor.

Note 8 - Board Designated Net Assets

Board designated net assets were reserved for the following:

	June 30,	
	2025	2024
Operating reserve	\$ 1,500,000	\$ 1,500,000
Total	<u>\$ 1,500,000</u>	<u>\$ 1,500,000</u>

Board designated net assets consisted of investments at June 30, 2025 and 2024.

CurePSP, Inc.

Notes to Financial Statements

June 30, 2025

Note 9 - Liquidity and Availability of Financial Resources

The Organization monitors liquidity and strives to maintain cash on hand to be available for its general expenditures, liabilities, and other obligations for on-going operations. In addition, a board designated operating reserve fund has been internally established by the board to provide an internal source of funds if deemed necessary.

As part of its liquidity management, the Organization relies on contributions, sponsorships, research roundtable, investment income and other revenue to fund its operations.

The following reflects the Organization's financial assets at June 30, 2025 that are available to meet cash needs for general expenditures within one year:

Cash and cash equivalents	\$ 2,589,958	
Investment	7,361,410	
Pledges receivable	<u>19,105</u>	
Total financial assets		\$ 9,970,473
Less amounts not available for general expenditure:		
Contributions with purpose restrictions	(2,262,583)	
Board designated fund	<u>(1,500,000)</u>	
Total amounts not available for general expenditures		<u>(3,762,583)</u>
Financial assets available to meet cash needs for general expenditures within one year		<u>\$ 6,207,890</u>

Note 10 - Subsequent Events

Subsequent events have been evaluated through April 17, 2026, the date the financial statements were available to be issued. Adjustments and disclosures have been made for all subsequent events that have occurred.